BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20230312T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20231105T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Zurich
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20230312T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20231105T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Istanbul
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:+03
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Africa/Djibouti
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240329
DTSTAMP:20240306T231313Z
CREATED:20240306T231313Z
LAST-MODIFIED:20240306T231313Z
UID:60533-1711324800-1711670399@globalbiodefense.com
SUMMARY:Preparedness Summit 2024
DESCRIPTION:The 2024 Preparedness Summit will be held 25-28 March 2024 in Cleveland\, Ohio. \nJoin more than 2\,500 attendees—who work in all levels of the government (federal\, state\, and local)\, emergency management\, volunteer organizations\, healthcare coalitions\, and academia—to share best practices\, build partnerships\, advance your skills\, and take away innovative solutions and practical strategies to address the vulnerabilities in our country’s health security system. \nHighlighted sessions include: \n\nAdvancing anthrax preparedness: Strengthening national defense against biological threats through cross-agency collaboration\nThe vital role of public health laboratories in response to surge events\nBioterrorism risk communications: Where are we now?\nPediatric concerns in a large-scale\, multi-state chemical\, biological\, radiological\, nuclear\, and explosive (CBRNE) mass casualty incident\nTularemia Emergency Response: Clinical Guidelines for Treatment and Prophylaxis After Intentional Release or Naturally Occurring Outbreaks of Francisella tularensis\nMedical toxicology and public health: A fruitful partnership illustrated by a popular awareness level course on chemical threats\nA National Special Pathogen System (NSPS) of care: Defining and expanding the structure for a more coordinated response to high consequence infectious diseases\nRegulatory framework for medical countermeasures response: Lessons from the expanded access programs for mpox therapeutics\nOperationalizing an early response framework for public health emergencies\nCultivating resilient public-clinical health networks to protect against infectious disease outbreaks\nBringing special pathogen care home: Virtual assessment model for at-home evaluation of suspected high-consequence infectious disease cases\nChaos to Clarity: The Post COVID-19 Transition\nEnhancing public health at the border: Mass vaccination initiatives\nAdvancing equity in mpox and COVID-19 diagnostics: Rapid summary of priority actions\nEnhancing state infectious disease preparedness and response capabilities for future threats via a discovery hub: INSPIRE: Readiness\nCHEMPACK program: Nerve agent antidotes\nPandemic Preparedness Training for Small Businesses\nPreparedness epidemiology: A local perspective\nMaking sense of the system: A One Health-based approach to assessing risk\, prioritizing action\, and building resilience\nWorking with the community to respond to a tripledemic of hepatitis A\, meningococcal disease\, and mpox affecting the same at-risk populations in Orange County\nA Case Study in Collaboration: Public Health\, Healthcare\, and Emergency Management Response to the East Palestine\, Ohio Train Derailment\nAdvancing national all-hazards hospital situational awareness\nFrom sewage to solutions: The possibilities and implications of wastewater monitoring\n\nA pre-conference workshop on Radiological and Nuclear Preparedness and Response will be held on 24 March 2024. \nPlease visit the 2024 Preparedness Summit website for more information and to register to attend.
URL:https://globalbiodefense.com/event/preparedness-summit-2024/
LOCATION:Huntington Convetion Center of Cleveland\, 300 Lakeside Avenue\, Cleveland\, OH\, 44113\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240329
DTSTAMP:20240307T004102Z
CREATED:20240307T004026Z
LAST-MODIFIED:20240307T004102Z
UID:60536-1711324800-1711670399@globalbiodefense.com
SUMMARY:20th Meeting of the Vector Control Advisory Group (VCAG)
DESCRIPTION:The 20th Meeting of the World Health Organization’s Vector Control Advisory Group (VCAG) will be held 25 March 2024 via online participation. \nHighlighted agenda items include: \n\nAedes SIT\nSpatial repellents\nTopical repellents\nVCAG operation\n\nThe sessions are for VCAG members or invitees only. \nAbout the VCAG \nAn independent evaluation of the public health value of innovative new tools\, technologies and approaches for vector control is needed to enable WHO to provide evidence-based advice to Member States on whether their deployment is justified. This is essential to ensure that scarce resources available for disease control are used to maximum impact. In order to assist WHO in developing public health policy on new tools\, the Vector Control Advisory Group (VCAG) assesses the public health value of new interventions and provides guidance on developing the evidence base required to inform such assessments. \nRead the report from the prior meeting of the VCAG in September 2023. \nPlease visit the WHO’s 20th Meeting of the Vector Control Advisory Group (VCAG) page for more information.
URL:https://globalbiodefense.com/event/20th-meeting-of-the-vector-control-advisory-group-vcag/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240329
DTSTAMP:20240206T194536Z
CREATED:20240206T194536Z
LAST-MODIFIED:20240206T194536Z
UID:59929-1711411200-1711670399@globalbiodefense.com
SUMMARY:Precision Med TRI-CON 2024
DESCRIPTION:The 31st International Precision Med TRI-CON 2024 will be held 26-28 March 2024 in San Diego\, California. \nVirtual participation is available as well as flexible registration to switch between in-person and virtual attendance across the conference. \nJoin thousands of international thought leaders to discuss the latest research\, technologies\, innovation and business models in implementing precision medicine\, biomarkers and companion diagnostics\, genomic medicine\, and precision health; innovation and market access strategies for at-home diagnostics\, point-of-care testing and molecular diagnostics for infectious diseases; liquid biopsy and advanced diagnostics for precision oncology\, including Multi-Cancer Early Detection and Minimal Residual Disease testing. \nEmerging implications of faster and cheaper sequencing\, AI and digital tools\, and spatial biology and single-cell multiomics in advancing precision medicine will be covered in 2024. \nHighlighted sessions and topics include: \n\nThe Shifting Landscape of Respiratory Pathogen Testing\nMultiplex Testing for Respiratory Pathogens—What Is the Right Fit?\nControlled Human Infection Models in Biomarker Development for Precision Medicine\nThe Host Response in Acute Infections and Sepsis: Potential Challenges and Benefits\nClinical Metagenomic Sequencing for Rapid Diagnosis of Infections\nDiagnostic Stewardship and Implementation of New Tests for Infectious Diseases in the Emergency Department\nDiagnosis of Invasive Fungal Infections by Microbial Metagenomics Sequencing\nAdvancing the AI in Diagnostics and Healthcare: Role of the Public-Private Partnership Model\nAugmenting AI-Powered Clinician Decision Support Tools for Severe Infection\nClinical Integration of Microbial Whole-Genome Sequencing\nHigh-Resolution Single-Cell and Spatial Technologies in Drug Development\nHome Testing for Infectious Diseases and Chronic Disease Monitoring\nScalable Solutions for Antibody Development and Manufacturing\nAccelerating Patient-Centered Diagnostics by Bringing Innovative Molecular Technologies to Point-of-Care Testing\nAt-Home Blood Microsampling: Innovations\, Opportunities\, and Challenges\nDirect Access Testing—What Can Be Done to Realize Its Full Potential?\nAdvances in Mobile and Digital Technologies for Point-of-Care Diagnostics\nRADically Speeding the Development and Validation of POC and Home-Based Diagnostics at the NIH: Lessons Learned and Future Directions\n\nPlease visit Cambridge Healthtech Institute’s Precision Med TRI-CON 2024 event page for more information and to register.
URL:https://globalbiodefense.com/event/precision-med-tri-con-2024/
LOCATION:Hilton San Diego Bayfront\, 1 Park Boulevard\, San Diego\, CA\, 92101-7897\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240401
DTEND;VALUE=DATE:20240405
DTSTAMP:20240206T233823Z
CREATED:20240206T233823Z
LAST-MODIFIED:20240206T233823Z
UID:59932-1711929600-1712275199@globalbiodefense.com
SUMMARY:World Vaccine Congress Washington 2024
DESCRIPTION:The World Vaccine Congress Washington 2024 will take place 1-4 April in Washington\, D.C. \nFrom basic research to commercial manufacture\, this one meeting covers the​ whole vaccine value chain where science\, government and manufacturers all come together to create ground- breaking progress.​ \nHighlighted sessions and topics include: \n\nGlobal Health mABs\nBiodefense & Preparedness Workshop\nVaccine Technology Workshop\nSpecial populations in clinical trials\nWhat are international agencies and industry doing to promote a One Health approach to global health risks\nAMR Workshop: Role of vaccines\, mABs\, phages and antibiotics\nPreparation of the CEPI Centralized Laboratory Network for Future Outbreaks\nRNA Workshop: From vaccines to therapeutics\nVaccine Delivery Workshop\nBiodegradable Lipid Nanoparticles for mRNA Vaccines with Room Temperature Stability\nInnovating vaccine development and implementation for impact\nSmallpox and Mpox live nonreplicating vaccine\nGlobal Health Workshop (NTDs)\nDeveloping novel partnership model for vaccines in EID\nImmune profiling: Building translational tools to improve mRNA vaccine performance\nVaccine manufacturing insights from Asia: Strengthening vaccine production capacity and capabilities\nChikungunya vaccine candidate\nThe evolving role of the ACIP\nThe future of COVID-19 vaccinations. Should we be developing broadly protective antigens or combinational vaccines?\nMonoclonal antibodies for prophylaxis of infectious disease\nWhat is the burden and uptake for RSV vaccines?\nThe future of global health: How to Advance detection and response capacity for Emerging & Re-emerging Pathogens in Africa & LMICs\nDecentralized trial solutions to improve access and health equity\nEmerging & re-emerging zoonotic diseases: what are our priority pathogens for spill over & pandemic risk?\nStudies to investigate the non-specific effects of vaccines and their importance in HICs and LMICs\nAn agile approach to PBMC collection in Vaccine Trials\nNirsevimab\, a monoclonal antibody for protection of all infants from RSV\n\nPlease visit the World Vaccine Congress Washington 2024 event site for more information and to register.
URL:https://globalbiodefense.com/event/world-vaccine-congress-washington-2024/
LOCATION:Walter E. Washington Convention Center\,  801 Mt Vernon Pl NW\, Washington\, DC\, 20001\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240402T130000
DTEND;TZID=America/New_York:20240402T143000
DTSTAMP:20240307T005932Z
CREATED:20240307T005932Z
LAST-MODIFIED:20240307T005932Z
UID:60538-1712062800-1712068200@globalbiodefense.com
SUMMARY:Uncertainty\, Trust\, and the Future of Public Health Communication
DESCRIPTION:A seminar on Uncertainty\, Trust\, and the Future of Public Health Communication will be held on 2 April 2024 online from 1:00-2:30 ET. \nThis program will explore public health communication in the context of a post – acute COVID world. How can we more effectively communicate public health messaging across different populations? What are the consequences of misinformation? How can we mitigate disinformation and disseminate accurate information to promote better health for all? \nThis event is cohosted by the Boston University School of Public Health and the BU College of Communication. \nPlease visit BU School of Public Health’s Uncertainty\, Trust\, and the Future of Public Health Communication to register.
URL:https://globalbiodefense.com/event/uncertainty-trust-and-the-future-of-public-health-communication/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240403
DTEND;VALUE=DATE:20240405
DTSTAMP:20240201T184017Z
CREATED:20240201T183935Z
LAST-MODIFIED:20240201T184017Z
UID:59781-1712102400-1712275199@globalbiodefense.com
SUMMARY:Artificial Intelligence and Automated Laboratories for Biotechnology: Leveraging Opportunities and Mitigating Risks
DESCRIPTION:This public workshop will discuss the use of artificial intelligence (AI) and automated laboratories for biotechnology. \nThe event will be held in-person at the National Academy of Sciences Building in Washington DC from 9:00am-5:00pm over two days (3-4 April 2024). Virtual attendances is available as well. \nThe workshop will consider opportunities to leverage AI and laboratory automation capabilities for discovery and development and opportunities to prevent the misuse of biotechnology. The workshop will also explore methods and approaches to identify\, track\, and forecast the domestic and international development of such technologies. \nThe transdisciplinary event will convene experts across sectors and utilize expertise to highlight recent advances and explore implications for the development and use of these technologies. \nThe workshop is being organized by a planning committee of the National Academies of Sciences\, Engineering\, and Medicine under the auspices of the Standing Committee on Advances and National Security Implications of Transdisciplinary Biotechnology \nWorkshop presentations and discussions will include the following topics: \n\nApplications of AI and automated laboratories for biotechnology discovery and development across various applications\nOpportunities for using AI and automated laboratories to prevent the misuse of biotechnology\nMethodologies and information for forecasting the development of AI and automated laboratory technologies\, and for assessing the technologies’ current and future capability gaps\, including approaches for identifying inaccuracies in science and technology materials that might change such assessments\nDrivers of innovation for AI and automated laboratory technologies\, including technical\, financial\, and policy drivers\nMethodologies for assessing the costs and benefits of investing or not investing in the development and adoption of such technologies for national security\, which could include methods from other fields that can be translated to biotechnology\n\nPlease visit the National Academies’ Artificial Intelligence and Automated Laboratories for Biotechnology: Leveraging Opportunities and Mitigating Risks event page to register.
URL:https://globalbiodefense.com/event/artificial-intelligence-and-automated-laboratories-for-biotechnology-leveraging-opportunities-and-mitigating-risks/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2024/02/nasem-artificial-intelligence-automated-labs-biotechnology-risk-reduction.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240403
DTEND;VALUE=DATE:20240405
DTSTAMP:20240201T205320Z
CREATED:20240201T200727Z
LAST-MODIFIED:20240201T205320Z
UID:59789-1712102400-1712275199@globalbiodefense.com
SUMMARY:Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions - Fourth Meeting
DESCRIPTION:In response to a Congressional request\, an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine is conducting a study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. \nThis is the fourth meeting of the committee of experts and will be conducted virtually. The meeting is a closed session and will not include a public session. \nWritten comments from the public may be submitted for the committee’s consideration. \nThe committee will evaluate: \n\nFlexibilities\, authorities\, or mechanisms available to regulators in the United States and the European Union applicable to rare diseases or conditions;\nThe consideration and use of supplemental data submitted during review processes in the United States and the European Union\, including data associated with open label extension studies and expanded access programs specific to rare diseases or conditions;\nAn assessment of collaborative efforts between United States and European Union regulators related to: product development programs under review; policies under development and those recently issued; and scientific information related to product development or regulation.\n\nPlease visit the National Academies’ Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information.
URL:https://globalbiodefense.com/event/processes-to-evaluate-the-safety-and-efficacy-of-drugs-for-rare-diseases-or-conditions/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240405T120000
DTEND;TZID=America/New_York:20240405T130000
DTSTAMP:20240318T014909Z
CREATED:20240214T215904Z
LAST-MODIFIED:20240318T014909Z
UID:59973-1712318400-1712322000@globalbiodefense.com
SUMMARY:GMU Schar School Master of Biodefense Information Session
DESCRIPTION:The George Mason University (GMU) Schar School of Policy and Government will be hosting a Master of Biodefense Information Session on Wednesday\, April 5\, noon to 1:00 p.m. ET (Virtual). \nProspective students are invited to attend to hear more about the Master of Biodefense program offered at the Schar School of Policy and Government at George Mason University. \nLearn about the program\, application process\, student experience\, and graduate outcomes. The program is offered in part-time\, full-time\, online\, in-person\, and hybrid formats. \n Learn more and register for the information session. \nGlobal Biodefense is an official media partner of the GMU Schar School of Policy and Government.
URL:https://globalbiodefense.com/event/gmu-schar-school-master-of-biodefense-information-session-2/
LOCATION:
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2024/02/gmu-schar-school-ms-biodefense-1200.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240408
DTEND;VALUE=DATE:20240412
DTSTAMP:20240307T015243Z
CREATED:20240307T015134Z
LAST-MODIFIED:20240307T015243Z
UID:60540-1712534400-1712879999@globalbiodefense.com
SUMMARY:Microbiology Society Annual Conference 2024
DESCRIPTION:The Microbiology Society Annual Conference 2024 will be held 8-11 April 2024 in Edinburgh\, Scotland. \nThe four-day conference consists of scientific symposia\, workshops\, fora\, professional development sessions\, Prize Lectures\, Hot Topics and much more. \nHighlighted sessions include: \n\nA protein-based molecular toolkit to study\, detect\, prevent and treat Oropouche fever\, a neglected tropical viral disease\nPhylodynamic analyses of A(H5N1) highly pathogenic avian influenza viruses reveal reassortment dynamics and diversification of host specificity\nAfrican Swine Fever Virus Multigene Family Interferon Inhibitory Proteins: Functions and Application to Vaccine Development\nUsing Protein Structure Prediction to Map Glycoprotein Diversity Reveals Defining Events in the Evolutionary History of the Flaviviridae\nComprehensive quantitative temporal proteomic\, transcriptomic and effectome analysis of mpox\nUsing serological responses to establish a correlate of protection against Chikungunya virus.\nA Copper Economy Underlies Synergy of Candida albicans and Staphylococcus aureus Dual-Species Biofilms\nZIKV sfRNA production: a tale of two hosts\n‘One Health’ Genomic Surveillance of Avian and Human Influenza A Viruses Through Environmental Wastewater Monitoring\nInfluenza A packaging and protein expression: in silico improvements in molecular characterisation\nEvaluation of virus transmission blockers in an in vivo pig influenza challenge model\nApplying Droplet Fluidics to Mycobacterial Drug Discovery\nDengue virus NS4A modulates NF-κB signalling and viral replication in Aedes aegypti mosquitoes\nA novel strategy to combat Group B Streptococcus neonatal disease by targeting interkingdom interactions with fungus Candida albicans\nAntibiotic resistance alters the ability of Pseudomonas aeruginosa to invade the respiratory microbiome\nInterferon-stimulated gene expression screening reveals genes with candidate antiviral activity against HCoV-OC43\nEpitranscriptomic Regulation of Influenza A Viruses\nZNFX1 is an RNA-regulated E3 ubiquitin ligase involved in antiviral responses\nThe differential antiviral activities of IFITM2/3 against SARS-CoV-2 are regulated by their N-terminal domain\nDetection of alpha and beta coronaviruses in bats in England during 2021-2023\nAssessing serological exposure to H5 avian influenza in humans in Malaysian Borneo\, along the East Asian – Australasian Flyway\n\nPlease visit the Microbiology Society Annual Conference 2024 website for more information.
URL:https://globalbiodefense.com/event/microbiology-society-annual-conference-2024/
LOCATION:Edinburgh International Conference Centre (EICC)\, 150 Morrison Street\, Edinburgh\, EH3 8EE\, United Kingdom
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240408
DTEND;VALUE=DATE:20240411
DTSTAMP:20240308T191134Z
CREATED:20240308T191050Z
LAST-MODIFIED:20240308T191134Z
UID:60551-1712534400-1712793599@globalbiodefense.com
SUMMARY:BV-BRC Viral Sub-Species Classification Workshop
DESCRIPTION:The Bacterial and Viral Bioinformatics Resource Center (BV-BRC) along with the CDC\, NCBI\, and NIAID\, are hosting a hybrid workshop on viral sub-species classification 8-10 April 2024. \nA critical aspect of the response to the COVID-19 pandemic was to trace\, classify\, and understand the evolving virus lineages\, their phenotypic differences\, and their impact on diagnostics\, vaccines\, and therapeutics. \nClassification and tracing of sub-species level variation has also been similarly important in outbreaks of viruses such as influenza\, HIV\, and monkeypox\, and has informed public health risk assessment and communication strategies. \nTo prepare for the next\, inevitable outbreak of virus disease\, the workshop will review various classification schemes developed for SARS-CoV-2 and other viruses\, examination of the methods and tools developed for classification\, discussion of the utility and impact of classification schemes on the public health response\, and review of lessons learned from past and current outbreaks. \nWorkshop speakers include: \n\nAnderson\, Tavis\, U.S. Department of Agriculture\nBahl\, Justin\, University of Georgia\nDonato\, Celeste\, Monash University\, Murdoch Children’s Research Institute\nHatcher\, Eneida\, National Center for Biotechnology Information\nHinrichs\, Angie\, University of California Santa Cruz\nKorber\, Bette\, Los Alamos National Labs\nKuhn\, Jens\, NIH/NIAID Integrated Research Facility\nLe Mercier\, Philippe\, Swiss-Prot group\, Swiss Institute of Bioinformatics\nLefkowitz\, Elliot\, University of Alabama at Birmingham\nNeher\, Richard\, University of Basel\nNjau\, Emma Peter\, Sokoine University of Agriculture\nRachel Colquhoun\, University of Edinburgh\nRoemer\, Cornelius\, University of Basel\nRota\, Paul\, U.S. Centers of Disease Control and Prevention\nSeto\, Don\, George Mason University\nSimmonds\, Peter\, University of Oxford\nSmith\, Derek J\, University of Cambridge\nWang\, Sean\, Minnesota Department of Health\nWarren\, Andrew\, University of Virginia\nZmasek\, Christian\, J.Craig Venter Institute\n\nThe outcome of the workshop will be to define best practices for establishing sub-species classification systems for these and other viruses that will be important in controlling future out breaks and potential pandemics. The valuable insights and best practices from this workshop will be widely disseminated. \nPlease visit the BV-BRC’s Viral Sub-Species Classification Workshop page for more information.
URL:https://globalbiodefense.com/event/bv-brc-viral-sub-species-classification-workshop/
LOCATION:NIAID Campus Rockville\, 5601 Fishers Lane\, Rockville\, MD\, 20892\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240409
DTEND;VALUE=DATE:20240413
DTSTAMP:20240203T020221Z
CREATED:20240203T020221Z
LAST-MODIFIED:20240203T020221Z
UID:59879-1712620800-1712966399@globalbiodefense.com
SUMMARY:Tropical and Emerging Infectious Diseases for Clinicians and Translational Scientists
DESCRIPTION:The Special Pathogens Excellence in Clinical Treatment\, Readiness\, & Education (SPECTRE) Center for Tropical Diseases (CTD) will host the 2024 Symposium on Tropical and Emerging Infectious Diseases for Clinicians and Translational Scientists from 9-12 April 2024 in Galveston\, Texas. \nThrough collaborative efforts at the University of Texas Medical Branch\, this symposium seeks to engage clinicians\, clinical investigators\, and field and laboratory researchers in discussion of current issues and future challenges in the field of tropical and emerging infectious diseases. The primary goal of this symposium is to foster an environment that facilitates exposure to diverse approaches to combat the emergence and reemergence of infectious diseases. \nPlease visit UTMB Health’s 2024 Symposium on Tropical and Emerging Infectious Diseases for Clinicians and Translational Scientists to register.
URL:https://globalbiodefense.com/event/tropical-and-emerging-infectious-diseases-for-clinicians-and-translational-scientists/
LOCATION:UTMB Health Education Center\, 301 11th St\, Galveston\, TX\, 77550\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240411
DTEND;VALUE=DATE:20240413
DTSTAMP:20240302T211201Z
CREATED:20240302T211201Z
LAST-MODIFIED:20240302T211201Z
UID:60496-1712793600-1712966399@globalbiodefense.com
SUMMARY:NIST Rapid Microbial Testing Methods Consortium Workshop
DESCRIPTION:The NIST-led Rapid Microbial Testing Methods (RMTM) Consortium is hosting the 4th annual workshop 11-12 April 2024 to update the community on RMTM Consortium efforts and to work on Consortium deliverables. \nOver the course of two days\, independent working sessions will be hosted\, with Day 1 open to the public and Day 2 for Consortium members only. \nThis open\, virtual workshop is free of charge. All interested parties are invited to Day 1\, including advanced therapy producers\, rapid microbial testing assay/instrument developers\, and cell reference material producers. \nNew members are being accepted into the Consortium. \nPlease visit NIST’s 2024 NIST Rapid Microbial Testing Methods Consortium Workshop website for more information. \nABOUT THE RMTM \nThe NIST Rapid Microbial Testing Methods (RMTM) Consortium addresses the need for measurements and standards\, including reference materials\, to increase confidence in the use of rapid testing for microbial contaminants in regenerative medicine and advanced therapy products. \nThe safety and quality of advanced therapies\, including cell therapy\, gene therapy\, and tissue engineered products\, must be maintained prior to patient administration. The culture-based compendial methods currently used to assess product purity (specifically to ensure absence of microbial contamination) typically take weeks\, which is inadequate for patients in urgent need of life-saving therapies. These methods are also incompatible with products that have a limited shelf-life and cannot meet good manufacturing practices required in process control and release testing. Alternative rapid microbial testing methods are needed to ensure fit for purpose safety assessments for this broad class of advanced therapeutics. \nThe NIST RMTM Consortium brings together experts across the regenerative medicine field including stakeholders in industry\, academia and government to address this need.
URL:https://globalbiodefense.com/event/nist-rapid-microbial-testing-methods-consortium-workshop/
LOCATION:
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240411
DTEND;VALUE=DATE:20240415
DTSTAMP:20240307T021155Z
CREATED:20240307T021155Z
LAST-MODIFIED:20240307T021155Z
UID:60547-1712793600-1713139199@globalbiodefense.com
SUMMARY:EAP2024 Mastercourse Update on Infectious Diseases in Paediatrics
DESCRIPTION:The European Academy of Paediatrics will host the EAP2024 Mastercourse Update on Infectious Diseases in Paediatrics from 11-14 April in Porto\, Portugal. \nHighlighted sessions and topics include: \n\nNew vaccines and schedules to prevent pneumococcus\nMeningococcus: How best to prevent a moving target?\nThe many faces of Streptococcus pyogenes infection in children\nAssessment of AMPK Levels in Neonates with Suspected Sepsis\nAssessment of the diagnostic accuracy of various Artificial Intelligence platforms\nFever and convulsions in a neonate\nEpidemiology and severity of acute viral respiratory infections in hospitalized children during\nand after the Covid-19 pandemic\nA challenging case of severe pneumonia\nIncrease in paediatric outpatient antibiotic prescribing following marked reductions during the\nCOVID-19 pandemic\nThe febrile neonate – tips to a successful lumbar puncture\nRecurrent skin infections in a child\nAn atypical pleural effusion\n\nPlease visit the EAP2024 Mastercourse Update on Infectious Diseases in Paediatrics site for more information.
URL:https://globalbiodefense.com/event/eap2024-mastercourse-update-on-infectious-diseases-in-paediatrics/
LOCATION:Sheraton Porto\, R. do Ten. Valadim 146\, Porto\, 4100-476\, Portugal
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240411T100000
DTEND;TZID=America/New_York:20240411T110000
DTSTAMP:20240326T223644Z
CREATED:20240326T223529Z
LAST-MODIFIED:20240326T223644Z
UID:60644-1712829600-1712833200@globalbiodefense.com
SUMMARY:Virus-Like Particles: Functionalities in Vaccinology and Research
DESCRIPTION:A webinar on Virus-Like Particles: Functionalities in Vaccinology and Research will be held on 11 April 2024. \nThe event is part of a series of research webinars presented by the Global Foot and Mouth Disease Research Alliance (GFRA). \nAbout the speaker: \nDr. Michael Puckette is a supervisory microbiologist for the Biologics Development Module\, or BDM\, located at the USDA National Bio and Agro-Defense Facility (NBAF). In his role\, Dr. Puckette will focus research on accelerating the technology transfer from research to commercial partners. In his previous role with the Department of Homeland Security-Science & Technology (DHS-S&T)\, Dr. Puckette worked at Plum Island Animal Disease Research Center developing Foot-and-Mouth Disease Virus (FMDV) vaccine technologies. \nPlease visit the Virus-Like Particles: Functionalities in Vaccinology and Research event page for more information.
URL:https://globalbiodefense.com/event/virus-like-particles-functionalities-in-vaccinology-and-research/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240415
DTEND;VALUE=DATE:20240418
DTSTAMP:20240206T235140Z
CREATED:20240206T235140Z
LAST-MODIFIED:20240206T235140Z
UID:59935-1713139200-1713398399@globalbiodefense.com
SUMMARY:Festival of Biologics USA 2024
DESCRIPTION:The Festival of Biologics USA 2024 will be held 15-17 April 2024 in San Diego\, California. \nThe Festival of Biologics aims to bring together senior biologics professionals across the value chain to showcase their research\, collaborate on challenges\, forge new connections and ultimately advance the industry to improve patient health. \nHighlighted sessions and topics include: \n\nTools and technologies advancing biotherapeutic design and development\nThe Landscape of Machine learning and Artificial Intelligence in drug development\nKeynote panel discussion: Engineering Next Generation Therapeutics – the future of antibody development\nAntibody fragments for toxic payload delivery: a platform for radiopharmaceutical therapy of solid tumors\nDevelopment of Checkpoint Agonist Antibodies for Immunological Diseases\nmRNA vaccines to prevent or treat autoimmune disorders: A paradigm shift\nTwo is Better Than One: Integration of in vitro and in vivo Bioanalytical Support by LCMS in the Development of Bispecific Antibodies\nExploring mutation resistant component of SARS-CoV-2 therapeutics\n\nPlease visit Terrapin’s Festival of Biologics USA 2024 website for more information and to register. \n 
URL:https://globalbiodefense.com/event/festival-of-biologics-usa-2024/
LOCATION:San Diego Convention Center\, 111 West Harbor Drive\, San Diego\, CA 92101\, 92101\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240415
DTEND;VALUE=DATE:20240420
DTSTAMP:20240203T045853Z
CREATED:20240203T045751Z
LAST-MODIFIED:20240203T045853Z
UID:59883-1713139200-1713571199@globalbiodefense.com
SUMMARY:Achieving Data Quality & Integrity In Maximum Containment Laboratories
DESCRIPTION:A FDA-UTMB Collaborative Education Program on Achieving Data Quality & Integrity In Maximum Containment Laboratories Non-Clinical Course will be held 15-19 April 2024 in Galveston\, Texas and online. \nThe four and one-half day training program is offered annually utilizing expert faculty from the U.S. Food and Drug Administration\, other government agencies\, academia\, and business and industry. In-person attendees participate in laboratory activities conducted in mock Biosafety Level (BSL) 2\, 3\, and 4 training laboratories to emphasize the differences between biosafety levels and the complexity of conducting laboratory activities in a BSL4 laboratory environment. \nThe Nonclinical Course includes expert faculty from AAALAC\, BARDA\, Battelle\, CEPI\, FDA\, NIAID\, NIH\, MRI Global\, Pfizer\, Texas Biomedical Research Institute\, UK Health Security Agency\, USAMRIID\, USDA\, UTMB\, Yale University School of Medicine and other institutions. \nHighlighted topics include: \n\nClinical Research at the Ebola Virus Disease Bedside\nApplying One Health Principles for Outbreak Response\nRegulatory Mechanisms to Facilitate Development/Approval/Licensure of Medical Countermeasures\nLife in a BSL-4 Suit\nDevelopment\, Characterization and Standardization of Bacterial and Viral Stocks\nAnimal Models for COVID\nAnimal Rule and Product Development\nData Standards for Animal Rule Studies\nOperationalizing BSL-4 in the Field\nPivotal Studies for NIAID Sponsored Animal Model Development\nQuality System Expectations for BARDA-sponsored studies\nQuality Assurance Auditing in BSL-4 laboratories\nUnforeseen Circumstances: Emergency Response in BSL-4 Laboratories\nAerosol Systems – Aerobiology with High Containment\nThe Role of the USDA National Bio and Agro-Defense Facility (NBAF)\nPublic Health Emergencies and Data Quality: Your Data Can Save Lives\nConducting Clinical Research in the Setting of an Outbreak: From HIV to Ebola to COVID-19\nInteractive Exercises in a Mock BSL-4 Training Laboratory\nBSL-4 Lab Tour\n\nThere are no fees associated with course attendance; however\, seating for in-person attendance is limited and interested participants will be placed on a wait-list once seats are filled. \nPlease visit UTMB’s Achieving Data Quality & Integrity In Maximum Containment Laboratories course page for more information and to register to attend.
URL:https://globalbiodefense.com/event/achieving-data-quality-integrity-in-maximum-containment-laboratories/
LOCATION:UTMB Health Education Center\, 301 11th St\, Galveston\, TX\, 77550\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240416
DTEND;VALUE=DATE:20240420
DTSTAMP:20240207T001036Z
CREATED:20240207T001036Z
LAST-MODIFIED:20240207T001036Z
UID:59938-1713225600-1713571199@globalbiodefense.com
SUMMARY:SHEA Spring Conference 2024
DESCRIPTION:The Society for Healthcare Epidemiology of America SHEA Spring Conference will take place 16-19 April 2024 in Houston\, Texas. \nSHEA members and non-members of all disciplines relating to Infection Prevention Programs\, Antibiotic Stewardship Programs\, Public Health\, Pharmacy\, Occupational Health\, Clinical Microbiology\, Quality Improvement\, and Patient Safety. If you are involved in infection prevention or infection control you should attend. \nHighlighted topics and sessions include: \n\nHow to design stewardship interventions and publish your results\nMicro 101 for the antimicrobial steward\nOverview of resources available for those new to healthcare epidemiology\nPKPD for the antimicrobial stewardship to the C-Suite\nMastering data visualization for antibiotic stewardship and healthcare epidemiology\nOne Health: People\, places and microbes\nResistant pathogens: gram-negative\, C. auris\nPromoting pharmacoequity in antimicrobial stewardship\nTransmission of infectious agents in healthcare\nTo certify or not to certify\, that is the question for healthcare epidemiologists\nCase studies in pediatric infection control\nInfection prevention in special outpatient settings\nStewardship collaboration with public health\nThe hospital epidemiologist as a clinical educator\nUtilizing next generation sequencing in healthcare epidemiology: public health and outbreak investigations\nIncorporating rapid diagnostics and biomarkers into stewardship interventions\n\nPlease visit the SHEA Spring Conference website for more information and to register to attend.
URL:https://globalbiodefense.com/event/shea-spring-conference-2024/
LOCATION:Westin Galleria Houston\, 5060 W Alabama St\, Houston\, TX\, 77056\, United States
ORGANIZER;CN="The Society for Healthcare Epidemiology of America (SHEA)":MAILTO:info@shea-online.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240418T110000
DTEND;TZID=America/New_York:20240418T120000
DTSTAMP:20240330T183242Z
CREATED:20240330T183242Z
LAST-MODIFIED:20240330T183242Z
UID:60731-1713438000-1713441600@globalbiodefense.com
SUMMARY:Patch Forward Prize Virtual Information Session
DESCRIPTION:Learn more about the Patch Forward Prize and ask questions at the April 18 virtual information session. \nThe Patch Forward Prize is a $50 million competition to advance microneedle patch-based RNA vaccines for COVID-19\, seasonal influenza\, and pandemic influenza. The Biomedical Advanced Research and Development Authority (BARDA) calls on vaccine developers and patch makers to partner and accelerate new vaccine technologies. \nDr. Robert Johnson\, Director of BARDA’s Medical Countermeasures Program\, will discuss the ambitious goals for the prize. The prize team will also present an in-depth overview of the three stages\, exploring submission expectations\, eligibility requirements\, and other key considerations. \nA video recording and summary of questions and answers will be published following the session. \nPlease visit BARDA’s Patch Forward Prize Virtual Information Session page to register.
URL:https://globalbiodefense.com/event/patch-forward-prize-virtual-information-session/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240421
DTEND;VALUE=DATE:20240425
DTSTAMP:20240207T030149Z
CREATED:20240207T030124Z
LAST-MODIFIED:20240207T030149Z
UID:59942-1713657600-1714003199@globalbiodefense.com
SUMMARY:2024 mRNA Technology Conference
DESCRIPTION:The 2024 mRNA Technology Conference will be held 21-24 April 2024 in Boston\, Massachusetts. \nThe event will showcase never before presented research and technology advances from both established leaders and early career professionals providing insights into present\, developing\, and future mRNA Applications. \nHighlighted program sessions include: \n\nManufacturing: IVT Process Optimization and Reactors Design\nAnalytical Characterization of mRNA\nOptimization & Design of mRNA for Future Therapeutics\n\nPlease visit AIChE’s 2024 mRNA Technology Conference website for more information.
URL:https://globalbiodefense.com/event/2024-mrna-technology-conference/
LOCATION:Revere Hotel Boston Common\, 200 Stuart St.\, Boston\, MA\, 02116\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240421
DTEND;VALUE=DATE:20240426
DTSTAMP:20240303T174832Z
CREATED:20240303T174832Z
LAST-MODIFIED:20240303T174832Z
UID:60502-1713657600-1714089599@globalbiodefense.com
SUMMARY:Chemical\, Biological\, Radiological\, Nuclear\, and Explosives (CBRNE) Sensing XXV
DESCRIPTION:SPIE’s Chemical\, Biological\, Radiological\, Nuclear\, and Explosives (CBRNE) Sensing XXV Conference will be held 22-25 April 2024 in National Harbor\, Maryland. \nThis conference provides an unprecedented forum for authors from government\, industry\, and academia to address a wide variety of CBRNE sensing issues\, technologies\, and advances in algorithms and signal process of threat related scenarios. \nThe sensing of CBRNE hazards is important to obtain “real-time” answers that allow actionable decisions to be made on-the-spot; to reduce the logistical burden by moving the analysis closer to the source of the sample; to rapidly screen materials to identify samples that need to be sent to a lab for additional analysis while minimizing the number of these samples; and to nondestructively analyze large\, valuable\, or immovable objects for which sampling is not possible. \nFurthermore\, defense communities around the world are increasingly interested in offloading forward decision making and analysis from soldiers to software\, which increases the need for more robust and accurate signal processing development to enable greater trust in detection outputs as the trend towards autonomous sensing continues. A strong reliance of CBRNE forensics is also required to enable attribution of these threats\, ideally in situ. In addition to protecting against battlefield CBRNE threats\, there is an increasing demand to protect borders and ports from the emergent threats of improvised explosive devices (IEDs)\, homemade explosives (HMEs)\, nuclear devices\, radiological dispersal devices\, and illicit narcotics. New and sophisticated radiation detection systems are also required for better protection of military personnel and civilians from radiological threats. \nAll of these sensor technologies are supported by advances in algorithms for sensor signal and data processing\, including sensor fusion\, machine learning/artificial intelligence. \nHighlighted topics include: \n\nBiothreat detection and identification using a carbon nanotube capture and containment array and surface enhanced Raman spectroscopy\nRapid detection of bioaerosol by measuring single particle differential circular polarization scattering (CIDS)\nCondensation-based growth of nanoparticles for real-time inertial-based capture and biothreat sensing\nBiolayer interferometry as a biological detection platform\nDetection of microorganisms in drinking water using fluorescence spectroscopy\nOptical constants measurements of liquids for modeling aerosolized threats\nAerosol release tracking via optical barcodes: aerosol sensor testing ground truth\nAerosol mass spectrometer for aerosol characterization at the ambient aerosol test facility\nEvaluation of emerging sensors to detect chemical exposure for food protection\nImproving Raman stand-off distance for the detection of chemical warfare agents\n\nConference Committee Members include: \n\nJason A. Guicheteau\, DEVCOM Chemical Biological Ctr\nChristopher R. Howle\, Defence Science and Technology Lab\nTanya L. Myers\, Pacific Northwest National Lab\nChristopher C. Carter\, Johns Hopkins Univ. Applied Physics Lab.\, LLC\nAugustus W. Fountain\, Univ. of South Carolina\nTimothy J. Johnson\, Pacific Northwest National Lab\nLars Landström\, FOI-Swedish Defence Research Agency\nAaron LaPointe\, U.S. Army CCDC C5ISR Ctr. Night Vision & Electronic Sensors Directorate\nTyler Miller\, Defense Threat Reduction Agency\nPaul M. Pellegrino\, DEVCOM Army Research Lab.\nSherrie S. Pilkington\, Intelligence Advanced Research Projects Activity\nNathaniel R. Gomer\, The Pennsylvania State Univ.\n\nThe conference track is part of the larger SPIE Defense + Commercial Sensing 2024 event. Please visit the Chemical\, Biological\, Radiological\, Nuclear\, and Explosives (CBRNE) Sensing XXV website for more information.
URL:https://globalbiodefense.com/event/chemical-biological-radiological-nuclear-and-explosives-cbrne-sensing-xxv/
LOCATION:Gaylord National Resort and Convention Center\, 201 Waterfront Street\, National Harbor\, MD\, 20745\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240422
DTEND;VALUE=DATE:20240425
DTSTAMP:20240218T231853Z
CREATED:20240218T231748Z
LAST-MODIFIED:20240218T231853Z
UID:60050-1713744000-1714003199@globalbiodefense.com
SUMMARY:Iraq Rapid Inactivation of High Consequence Pathogens Workshop
DESCRIPTION:On behalf of the US Defense Threat Reduction Agency (DTRA)\, Sandia National Laboratories will host “Developing Laboratory Best Practices for Rapid Inactivation of High Consequences Pathogens and Sensitive Equipment Workshop” in April 2024. Stakeholders from Central Veterinary Laboratories (CVL) and Central Public Health Laboratories (CPHL) from the Government of Iraq (GOI) and Iraqi Kurdistan Region (IKR) who work with high consequence pathogens will attend to develop a long-term sample life cycle management plan. \nThis Cooperative Threat Reduction (CTR) initiative will be held in Istanbul from 22 April to 24 April. \nThis training will consist of three Phases: \nPhase I will consist of virtual sessions with institutions before and after the training event to review their laboratory’s current sample retention practices\, decontamination methods and efficacy\, discuss cost considerations for sustainability\, and work to review and draft standardized standard operation procedures (SOPs) on the destruction and disposal of the laboratory’ pathogen repository and sensitive equipment. \nPhase II will consist of a three-day workshop held in April 2024\, in Istanbul\, Turkey. Phase II topics will include rapid inactivation/destruction of pathogens and sensitive equipment\, the role of material control and accountability in biosecurity\, different types of administrative controls with a focus on biorisk management (BRM) documentation\, sample inventory system components\, the process of effective planning for reaching institutional BRM goals\, and finally how to safeguard laboratory pathogens. \nPhase III will consist of a virtual session where SNL/GCBS will facilitate Iraqi mentors identified from CVL and CPHL target laboratories in Bagdad and Erbil in conducting a virtual “Regional Rapid Inactivation Best Practices Training” for additional nominated participants from regional animal and public health laboratories to review the final developed practices\, policies\, and standard operating procedures (SOPs) for sample life cycle and rapid inactivation of high consequence pathogens and sensitive equipment management plan. \nLearn more and by visiting the Sandia’s Global Chemical and Biological Security Events page or contacting contact Sarah Calcutt.
URL:https://globalbiodefense.com/event/iraq-rapid-inactivation-of-high-consequence-pathogens-workshop/
LOCATION:Istanbul\, Istanbul\, Turkey
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240422
DTEND;VALUE=DATE:20240427
DTSTAMP:20240218T230730Z
CREATED:20240218T230603Z
LAST-MODIFIED:20240218T230730Z
UID:60045-1713744000-1714175999@globalbiodefense.com
SUMMARY:Global Biorisk Management - East Africa 2nd Cohort Foundational Training
DESCRIPTION:On behalf of the US Defense Threat Reduction Agency (DTRA)\, Sandia National Laboratories will host a series of virtual and in-person training workshops in Antananarivo\, Madagascar to support ongoing efforts to build participants’ ability to train others and create a global biorisk management trainers’ network across East Africa. \nBy the end of the four workshops\, participants will have access to the Global Biorisk Management Curriculum (GBRMC)\, core documents (Standard Operating Procedure Templates\, Biorisk Manuals\, Respiratory Protection Manuals\, and more). The GBRMC is a repository of 40+ training courses centered on the principles and best practices of biorisk management (biosafety and biosecurity). \nRemote meetings will begin in advance of in-person training scheduled for 22 – 26 April. \nLearn more and register for the East African BRM Trainer’s Network by visiting the Sandia’s Global Chemical and Biological Security Events page or contacting contact Jessica Quinn.
URL:https://globalbiodefense.com/event/global-biorisk-management-east-africa-2nd-cohort-foundational-training/
LOCATION:Antananarivo\, Madagascar\, Antananarivo\, Madagascar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20240207T031055Z
CREATED:20240207T031020Z
LAST-MODIFIED:20240207T031055Z
UID:59946-1713830400-1714089599@globalbiodefense.com
SUMMARY:World Orphan Drug Congress 2024
DESCRIPTION:The World Orphan Drug Congress will be held 23-25 April 2024 in Boston\, Massachusetts. \nThe event brings together leading pharmaceutical and biotech companies\, government and regulatory authorities\, patient advocacy groups\, payers\, investors and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies. \nHighlighted agenda topics include: \n\nTransformative policies and strategies for orphan drug accessibility\nNIH as your technology development and commercialization partner\nCurrent best practices for diversity in clinical trials\nHow to successfully achieve reimbursement in rare diseases: From inception to submission\nStrategies to save time and cost in rare disease drug development\nAccess for rare disease patients in Europe and beyond\nCommercialization in rare disease\nUnderstanding the implications of state policies on patient access\nUsing biomarkers to accelerate development of disease modifying therapies for rare disease\nIndustry perspectives: Partnering in the rare disease space\n\nPlease visit Terrapin’s World Orphan Drug Congress 2024 site for more information.
URL:https://globalbiodefense.com/event/world-orphan-drug-congress-2024/
LOCATION:Boston Convention & Exhibition Center (BCEC)\, 415 Summer St\, Boston\, MA\, 02210\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240424T100000
DTEND;TZID=America/New_York:20240424T120000
DTSTAMP:20240301T220152Z
CREATED:20240301T220132Z
LAST-MODIFIED:20240301T220152Z
UID:60487-1713952800-1713960000@globalbiodefense.com
SUMMARY:General Considerations of Using NHP in Preclinical Ocular Drug Research
DESCRIPTION:This webinar will discuss the basic biology of the NHP eye compared to human and other species (rabbit and rodents) in anatomy and physiology\, as well as the advantages and concerns of using the NHP eye in preclinical ocular research and drug discovery. \nExperts will share major background findings in ocular toxicity studies in different types of test articles (biologics and gene therapy) in different species. \nThe origin and principle of immunogenicity in preclinical ocular studies will be discussed\, along with representative images of ocular immunogenicity findings\, and experience in risk mitigation strategies. \nThe speaker will introduce NHP ocular disease models\, and present examples of using these models for efficacy studies with different routes of administration. Ophthalmic endpoints for ocular efficacy and toxicity studies will be discussed\, with typical ocular findings related to the immune and test articles. \nPlease visit SOT’s Ocular Toxicology event page to register for this webinar.
URL:https://globalbiodefense.com/event/general-considerations-of-using-non-human-primate-in-non-clinical-ocular-drug-research/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Zurich:20240425T131500
DTEND;TZID=Europe/Zurich:20240425T144500
DTSTAMP:20240420T172450Z
CREATED:20240420T172433Z
LAST-MODIFIED:20240420T172450Z
UID:61072-1714050900-1714056300@globalbiodefense.com
SUMMARY:BWC Scientific and Technological Advisory Mechanism
DESCRIPTION:This Biological Weapons Convention Working Group Friends of the Chair Webinar Series event is intended to support ongoing activities of the BWC Working Group and stimulating thinking and discussion around a mechanism during the intersessional period. \nThe event will consist of an expert panel followed by a moderated question-and-answer session with the audience. \nThe event is open to state representatives and experts working on or interested in issues pertaining to scientific and technological review of the BWC. \nOther events in this series include: \n\nBWC: Confidence Building and Transparency (6 May 2024)\nBWC: National Implementation (8 May 2024)\nBWC: Compliance and Verification (13 May 2024)\n\nPlease visit the UNIDR’s BWC: Scientific and Technological Advisory Mechanism webinar page to register.
URL:https://globalbiodefense.com/event/bwc-scientific-and-technological-advisory-mechanism/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240501T120000
DTEND;TZID=America/New_York:20240501T120000
DTSTAMP:20240420T143500Z
CREATED:20240420T143500Z
LAST-MODIFIED:20240420T143500Z
UID:61069-1714564800-1714564800@globalbiodefense.com
SUMMARY:Comms Crash Course: Developing and Producing Videos to Expand Public Health Messaging
DESCRIPTION:Comms Crash Course: Developing and Producing Videos to Expand Public Health Messaging will cover best practices for using video to broaden outreach\, engage with diverse populations\, and foster healthier communities. \nTopics will include: \n\nCrafting compelling narratives that resonate with audiences and the importance of storytelling in public health messaging.\nFoundational aspects of creating a video\, including planning\, shooting\, and editing to develop engaging content.\nStrategies for maximizing video reach and engagement across platforms.\n\nIn an era dominated by digital content\, learning to craft compelling videos is essential for amplifying public health messages. This webinar is designed for public health communicators eager to harness the full spectrum of video production tools and storytelling techniques to captivate\, educate\, and inspire their local communities. \nPlease visit the Public Health Communications Collaborative’s Comms Crash Course: Developing and Producing Videos to Expand Public Health Messaging website to register.
URL:https://globalbiodefense.com/event/comms-crash-course-developing-and-producing-videos-to-expand-public-health-messaging/
LOCATION:https://us06web.zoom.us/webinar/register/4717132946626/WN_HQIxhL-7SaS3fvqPuiXI0A
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240502T120000
DTEND;TZID=America/New_York:20240502T130000
DTSTAMP:20240411T173247Z
CREATED:20240214T234356Z
LAST-MODIFIED:20240411T173247Z
UID:59977-1714651200-1714654800@globalbiodefense.com
SUMMARY:GMU Schar School Master of Biodefense Information Session
DESCRIPTION:The George Mason University (GMU) Schar School of Policy and Government will be hosting a Master of Biodefense Information Session on Thursday\, May 2\, noon to 1:00 p.m. ET (Virtual). \nProspective students are invited to attend to hear more about the Master of Biodefense program offered at the Schar School of Policy and Government at George Mason University. \nLearn about the program\, application process\, student experience\, and graduate outcomes. The program is offered in part-time\, full-time\, online\, in-person\, and hybrid formats. \n Learn more and register for the information session. \nGlobal Biodefense is an official media partner of the GMU Schar School of Policy and Government.
URL:https://globalbiodefense.com/event/gmu-schar-school-master-of-biodefense-information-session-3/
LOCATION:
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2024/02/gmu-schar-school-ms-biodefense-1200.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240507T100000
DTEND;TZID=America/New_York:20240507T160000
DTSTAMP:20240327T155732Z
CREATED:20240327T155732Z
LAST-MODIFIED:20240327T155732Z
UID:60646-1715076000-1715097600@globalbiodefense.com
SUMMARY:Masters of the Air: Overcoming Airborne Pathogens Indoors
DESCRIPTION:Masters of the Air: Overcoming Airborne Pathogens Indoors will be held on 7 May 2024 in Washington\, DC. \nThe focus of this meeting will be to provide the Bipartisan Commission on Biodefense with a better understanding of: \n\nHow the federal government currently addresses indoor air quality\nNew scientific and technological advances for indoor air quality\nHow enhancing indoor air quality can help prevent the spread of pathogens\n\nPlease visit the Bipartisan Commission on Biodefense’s Masters of the Air: Overcoming Airborne Pathogens Indoors page for more information.
URL:https://globalbiodefense.com/event/masters-of-the-air-overcoming-airborne-pathogens-indoors/
LOCATION:Hudson Institute\, 1201 Pennsylvania Avenue Northwest\, #400\, Washington\, DC\, 20004\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240515T160000
DTEND;TZID=America/Los_Angeles:20240515T190000
DTSTAMP:20240507T155352Z
CREATED:20240507T154417Z
LAST-MODIFIED:20240507T155352Z
UID:61182-1715788800-1715799600@globalbiodefense.com
SUMMARY:BARDA Accelerator Network Launch Event
DESCRIPTION:The BARDA Accelerator Network Launch Event will be held 15 May 2024 both virtually and in-person in Irvine\, CA. \nThe Biomedical Advanced Research and Development Authority (BARDA)\, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services unveiled the next generation of the BARDA Accelerator Network by announcing University Lab Partners (ULP) as the new Diagnostics/Medical Devices Hub and Start2 as the new Therapeutics/Vaccines Hub. \nThe I-CREATE Hub will support the development and acceleration of game-changing diagnostics and medical devices to detect\, prevent\, or respond to medical consequences that result from health security threats. \nTogether the first two Hubs will forge the way for the launch of three additional Hubs in 2024 to build a global network to foster the health security innovation ecosystem with commercialization and wraparound support and enable rapid development\, evaluation\, validation\, and commercialization of Medical Countermeasures (MCMs). \nAdvanced registration for the launch event is required.
URL:https://globalbiodefense.com/event/barda-accelerator-network-launch-event/
LOCATION:UCI Research Park\, 5270 California Avenue\, Irvine\, CA\, 92617\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240523
DTEND;VALUE=DATE:20240525
DTSTAMP:20240201T205508Z
CREATED:20240201T204725Z
LAST-MODIFIED:20240201T205508Z
UID:59803-1716422400-1716595199@globalbiodefense.com
SUMMARY:Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions - Fifth Meeting
DESCRIPTION:In response to a Congressional request\, an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine is conducting a study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. \nThis is the fifth meeting of the committee of experts and will be conducted virtually. The meeting is a closed session and will not include a public session. \nThe committee will evaluate: \n\nFlexibilities\, authorities\, or mechanisms available to regulators in the United States and the European Union applicable to rare diseases or conditions;\nThe consideration and use of supplemental data submitted during review processes in the United States and the European Union\, including data associated with open label extension studies and expanded access programs specific to rare diseases or conditions;\nAn assessment of collaborative efforts between United States and European Union regulators related to: product development programs under review; policies under development and those recently issued; and scientific information related to product development or regulation.\n\nBased on its information gathering and internal deliberations\, the committee will develop a report with its findings\, conclusions\, and recommendations for actions that Congress\, federal agencies\, the pharmaceutical industry\, and nongovernmental organizations can take to support collaborative efforts. \n\n\nThe Third Meeting of the committee on the Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union was held 6-7 Feb 2024.\nThe Fourth Meeting of the committee on the Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union was held 3-4 Apr 2024.\n\n\nPlease visit the National Academies’ Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information.
URL:https://globalbiodefense.com/event/processes-to-evaluate-the-safety-and-efficacy-of-drugs-for-rare-diseases-or-conditions-in-the-united-states-and-the-european-union-fifth-meeting/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
END:VEVENT
END:VCALENDAR